Phaeochromocytoma and paraganglioma (PPGL) are chromaffin cell tumours that require
timely diagnosis because of their potentially serious cardiovascular and sometimes life …

Insufficient tissue oxygenation, or hypoxia, contributes to tumor aggressiveness and has a
profound impact on clinical outcomes in cancer patients. At decreased oxygen tensions …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Objective: The aim was to formulate clinical practice guidelines for pheochromocytoma and
paraganglioma (PPGL). Participants: The Task Force included a chair selected by the …

Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma
carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA …

Succinate is an important metabolite at the cross-road of several metabolic pathways, also
involved in the formation and elimination of reactive oxygen species. However, it is …

A molecular biology–based taxonomy has been proposed for pheochromocytoma and
paraganglioma (PPGL). Data from the Cancer Genome Atlas revealed clinically relevant …

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that
arise from chromaffin cells of the adrenal medulla and the sympathetic/parasympathetic …

Paragangliomas and phaeochromocytomas are neuroendocrine tumours whose
pathogenesis and progression are very strongly influenced by genetics. A germline mutation …

Context Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and
knowledge of the natural history is limited. Objective We aimed to describe baseline …